Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14666194 | 1.00 | PGR (0.70) | PGRARNR3C1 | |
| SCHEMBL20235465 | 1.00 | PGR (0.70) | PGRARNR3C1 | |
| SCHEMBL5495772 | 0.91 | AR (0.72) | PGRARNR3C1 | |
| SCHEMBL20235207 | 0.88 | PGR (0.69) | PGRARNR3C1 | |
| SCHEMBL14666141 | 0.88 | PGR (0.69) | PGRARNR3C1 | |
| SCHEMBL14656260 | 0.88 | PGR (0.69) | PGRARNR3C1 | |
| SCHEMBL20235184 | 0.85 | AR (0.67) | PGRARNR3C1 | |
| SCHEMBL14656658 | 0.85 | AR (0.67) | PGRARNR3C1 | |
| SCHEMBL14666165 | 0.85 | AR (0.67) | PGRARNR3C1 | |
| SCHEMBL14666071 | 0.84 | AR (0.82) | PGRARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736918-B1 | PROGESTERONE ANTAGONISTS | EVESTRA INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180155386-A1 | PROGESTERONE ANTAGONISTS | EVESTRA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20130029953-A1 | PROGESTERONE ANTAGONISTS | EVESTRA, INC. | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155386-A1 | PROGESTERONE ANTAGONISTS | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 41/4885NR3C1 37/4885 |
| US-20130029953-A1 | PROGESTERONE ANTAGONISTS | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 41/4885NR3C1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.